AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06742528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: ferrous sulphate in a dose of 6mg/kg/day of elemental iron once daily for 8 weeks orally in syrup form.
Study NCT06742528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Polymaltose Complex
Description: Iron Polymaltose complex in a dose of 6mg/kg/day of elemental iron once daily orally for 8 weeks.
Study NCT06742905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Robot-guided echo
Description: This echo will be performed by a remote sonographer, though a robot
Study NCT06742905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard echocardiogram
Description: Echocardiogram acquired by a sonographer at the patient's bedside
Study NCT06741774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trabecular Meshwork Microstent Drainage System
Description: The device is implanted on the functional trabecular meshwork with head in schlemm canal and tail in anterior chamber. There is a hollow tube connecting schlemm canal and anterior chamber. The device can promote external drainage of aqueous humor to reduce intraocular pressure.
Study NCT06741774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification
Description: Eyes with OAG and cataracts randomly divided into control group that were planned for phacoemulsification alone.
Study NCT06741878 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Involves participants engaging in physical training group sessions in light-to-moderate intensity.
Study NCT05161780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
Study NCT06741878 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial
Description: Involves participants engaging in selected board and card games which require cognitive and socialization skills to play in a group setting of 2-4 people.
Study NCT06741878 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional
Description: Involves participants attending dietary classes taught by a certified dietitian, including individualized consultation.
Study NCT06508710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients randomized in this group will receive an intravenous ketamine in addition to venlafaxine for one week (on Days 1, 4 and 7)
Study NCT06508710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized in this group will receive an intravenous placebo in addition to venlafaxine for one week (on Days 1, 4 and 7)
Study NCT06472167 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing exercises
Description: Breathing exercises as diaphragmatic breathing exercises and pursued lip breathing and incentive spirometry
Study NCT05114460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naloxone
Description: Intranasal Naloxone
Study NCT05114460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: Intranasal Naloxone
Study NCT05114460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Intranasal Naloxone
Study NCT05114460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Marijuana
Description: Vaped Marijuana
Study NCT05114460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marijuana
Description: Vaped Marijuana
Study NCT05114460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Vaped Marijuana
Study NCT04613453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Infusion
Description: Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.
Study NCT04613453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Infusion
Description: Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
Study NCT05879107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).
Study NCT05879107 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSVPreF3 OA investigational vaccine
Description: One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).
Study NCT05879107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV20
Description: One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1
Study NCT05879107 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV20
Description: One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1
Study NCT05996185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Mogamulizumab is a humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis.
Study NCT05996185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-EPOCH Protocol
Description: EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma.
Study NCT04660201 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: AV7909 (Liquid Formulation) is an investigational vaccine that is a preformulated, sterile, milky-white suspension for IM injection. It consists of the Anthrax Vaccine Adsorbed (AVA) bulk drug substance and CPG 7909 adjuvant
Study NCT04660201 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AV7909
Description: AV7909 (Lyophilized Formulation) is a thermostable, lyophilized version of the liquid AV7909 formulation. Sterile, milky-white suspension for intramuscular injection. It consists of polysorbate 80, CPG7909 adjuvant and AVA bulk drug substance
Study NCT05239416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting
Description: Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the healed ulcer area under complete aseptic operative setting
Study NCT06285617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-week predisone+1-week celecoxib
Description: 20 and 10 mg prednisone in the morning and afternoon, respectively, daily for 1 week; in the second week, these participants received 400 mg celecoxib (a type of nonsteroidal anti-inflammatory drug) on day 1 and 200 mg twice daily for the remaining 6 days until celecoxib withdrawal.
Study NCT06108479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF6215
Description: Immunotherapy (cytokine) targeting effector cells.
Study NCT06285617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-weeks predisone
Description: 20 and 10 mg prednisone in the morning and afternoon, respectively, daily in the first week, and then reduced by 5 mg/week from the second week until withdrawal in the sixth week.
Study NCT04150458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluorocholine PET/CT.
Description: 18F-fluorocholine positron emission tomography / computed tomography
Study NCT06389370 — intervention group
Intervention type: OTHER
Intervention: HU-DBI questionnaire
Description: a questionnaire published by Hiroshima University (HU-DBI) to measure the Knowledge, Attitude and Behaviour of dental students through different levels of their academic years.
Study NCT06098495 — intervention group
Intervention type: GENETIC
Intervention: search for epigenetic profile of infertility
Description: examine the epigenetic profile of DNA extracted from MGCs and blood sample
Study NCT05063201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 MG
Description: Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
Study NCT05063201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
Study NCT05156983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-330
Description: Participants will receive TAK-330, 25 IU/kg single intravenous infusion on Day 1 and an additional dose of 25 IU/kg TAK-330 can be administered if required.
Study NCT05156983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC 4F-PCC
Description: Participants will receive 4F-PCC as SOC on Day 1. The dose and infusion speed of the SOC 4F-PCC will be based on local institutional protocols. An additional dose of SOC 4F-PCC not exceeding total dose of 50 IU/kg or 5,000 IU, whichever is smaller can be given during the surgery if required.
Study NCT06657534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Push-pull technique
Description: push-pull technique as described by McBride et al, J Infus Nurs 2018
Study NCT06657534 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SOC (Standard of care)
Description: Standard of care method to obtain blood with waste blood
Study NCT06161974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olutasidenib + TMZ
Description: Olutasidenib 150 mg PO BID + Temozolomide 200 mg/m2 PO QD
Study NCT06580197 — intervention group
Intervention type: OTHER
Intervention: Auricular Acupoint Therapy
Description: Ear point diagnosis and treatment is one of acupuncture and moxibustion methods, which originates from the theory of acupuncture and moxibustion meridians and is the product of the combination of modern Chinese medicine and western medicine, including two parts: auricular acupoint diagnosis and auriculotherapy. Ear point diagnosis refers to the determination of auricle positive reaction points through vision, touch, pressure and other methods to diagnose diseases in some parts of the body on the basis of ear point theory. Ear point treatment refers to the use of certain therapeutic devices on ear points to achieve the purpose of prevention and treatment of diseases by stimulating ear points, which are often carried out simultaneously in clinical practice.
Study NCT05878964 — intervention group
Intervention type: OTHER
Intervention: EQ-5D-5L questionnaire
Description: Quality of life evaluation questionnaire
Study NCT05878964 — intervention group
Intervention type: OTHER
Intervention: FACT-G (Functional Assessment of Cancer Therapy - General)
Description: Quality of life evaluation questionnaire
Study NCT05878964 — intervention group
Intervention type: OTHER
Intervention: FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)
Description: Self reported evaluation of cutaneous toxicity questionnaire.
Study NCT06004895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actual IPL
Description: Five light pulses along lower lid region of one eye of the participant ranging from 59 to 69 Joules (J) over an area of 2.5cm by 4.5cm for each pulse
Study NCT06004895 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham IPL
Description: Simulated five light pulses along lower lid region of the other eye of the same participant
Study NCT06004895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLLT
Description: Mask with LEDs transferring a total of about 32 J/cm\^2 of energy to facial and eyelids region with their eyes closed
Study NCT06004895 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: LLLT
Description: Mask with LEDs transferring a total of about 32 J/cm\^2 of energy to facial and eyelids region with their eyes closed
Study NCT05796154 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ear blood pressure monitor
Description: The ear blood pressure monitor is a biometric monitoring device that collects blood pressure non-invasively from the ear.
Study NCT06537622 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Implementation group
Description: Implementation strategies to increase uptake of the clinical practice guidelines for earlier diagnosis of cerebral palsy
Study NCT06537622 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: No active implementation strategies
Study NCT04834128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCB008
Description: administration of gamma delta T cells by IV bolus injection
Study NCT06167694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-8080; Dalpiciclib Isethionate Tablets
Description: HRS-8080 combined with Dalpiciclib Isethionate Tablets
Study NCT05571488 — intervention group
Intervention type: OTHER
Intervention: Electronic surveys
Description: Online questionnaires will be used to collect data, at recruitment and follow-up once a year
Study NCT05571488 — intervention group
Intervention type: OTHER
Intervention: Qualitative Interviews
Description: Remote focus groups or semi-structured interviews will be proposed to a subsample of the participants, first the year after recruitment and then every two years
Study NCT06656936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PharmFIT
Description: The PharmFIT intervention involves the following components: referral notice to patient, FIT ready notification, FIT ready reminders, FIT distribution, FIT completion reminders, negative and positive results notification, patient navigation support.
Study NCT04984902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporal therapy
Description: Extracorporal therapy
Study NCT06657482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed school start time
Description: The intervention group will start school two hours later on Mondays (at 10.15 ± 15 min) and one hour later on Tuesdays (9.15 ± 15 min) and to ordinary school start time (8.15 ± 15 min) for the rest of the week
Study NCT06656273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FT LCP
Description: FT LCP is a behavior change software application, used as an adjunct to the standard National Diabetes Prevention Program
Study NCT06656780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIT
Description: Participants will undergo 2 day (8 hours each) Stress Inoculation Training . This will be done in 3 steps:~Step 1: focus on education about the human body and brain and shift to hands on skills practice to improve performance in stressful conditions and is designed to improve self-and-situational awareness and the ability to manipulate reactions and responses in the body on purpose to enhance performance~Step 2: focuses on improving mental self-awareness and gaining skills in Mental Agility and Mental Flexibility~Step 3: participants will have specific simulations and real-world opportunities to practice the skills learnt.
Study NCT06656780 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DCA-FF
Description: Participants will undergo 8-week Standard Firefighting Training
Study NCT06656780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DCA-FF
Description: Participants will undergo 8-week Standard Firefighting Training
Study NCT06657339 — intervention group
Intervention type: PROCEDURE
Intervention: Therapeutic endoscopy endosleeve using a gastric suturing device (OverStitch™/Endomina™)
Description: The patient will undergo therapeutic endoscopy under general anesthesia, either as outpatient or inpatient care, based on the recommendations of the investigating physician, taking into account anesthetic risks and comorbidities. Two CE-marked gastric suturing devices may be used at the discretion of the investigating center based on their practices~OverStich™ allows for tissue fixation via a gastroscope, creating a durable suture through a transabdominal fixation technique. The procedure lasts about 45 minutes and includes measures to prevent vomiting.~Endomina™ is a single-use device that captures the gastric mucosa to create successive plications, allowing for effective suturing along the greater curvature of the stomach.
Study NCT05750914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Broadband Light
Description: Broadband Light treatment using standard protocol
Study NCT06664567 — intervention group
Intervention type: BEHAVIORAL
Intervention: Colorectal cancer screening test
Description: delivery of colorectal cancer screening test by GP
Study NCT06673355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dental implant prosthesis
Description: patients will receive frameworks made of high-performance polymer filled with nano zirconia and carbon
Study NCT06673355 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dental implant prosthesis
Description: patients will receive frameworks made of high-performance polymer filled with nano zirconia and carbon
Study NCT05178901 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHV02
Description: live, recombinant virus consisting of vesicular stomatitis virus (VSV; Indiana) with the gene for the Zaire ebolavirus glycoprotein (GP) (EBOV GP) replacing the gene for the VSV GP; in addition, the Nipah virus (NiV) G protein is also inserted and expressed. The vaccine is administered as a single intramuscular injection
Study NCT05178901 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactated Ringer's Solution. The placebo will be administered as a single intramuscular injection
Study NCT04109079 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary lymph node dissection
Description: Participants will undergo removal of at least level I and II axillary lymph nodes.
Study NCT04109079 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Axillary radiotherapy
Description: Axillary radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
Study NCT04109079 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Breast or chest wall radiotherapy
Description: Breast or chest wall radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
Study NCT04109079 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Breast or chest wall radiotherapy
Description: Breast or chest wall radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
Study NCT06046560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor, GLP-1 RA
Description: Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention.
Study NCT06046560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor, GLP-1 RA
Description: Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention.
Study NCT06046560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education-First
Description: For the first 2-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 2 months, be invited to participate in the remote clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for therapy.
Study NCT04884087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA; Metricwire) Prompts 3x/day
Description: Participants receive 3 EMA survey prompts daily for the duration of the study.